TY  - JOUR
AU  - Del Rio, Carmen
AU  - Cantarero, Irene
AU  - Palomares, Belen
AU  - Gomez-Cañas, Maria
AU  - Fernandez-Ruiz, Javier
AU  - Pavicic, Carolina
AU  - Garcia-Martin, Adela
AU  - Luz Bellido, Maria
AU  - Ortega-Castro, Rafaela
AU  - Perez-Sanchez, Carlos
AU  - Lopez-Pedrera, Chary
AU  - Appendino, Giovanni
AU  - Calzado, Marco A
AU  - Muñoz, Eduardo
PY  - 2018
DO  - 10.1111/bph.14450
UR  - http://hdl.handle.net/10668/12741
T2  - British journal of pharmacology
AB  - The endocannabinoid system and PPARγ are important targets for the development of novel compounds against fibrotic diseases such as systemic sclerosis (SSc), also called scleroderma. The aim of this study was to characterize VCE-004.3, a novel...
LA  - en
PB  - John Wiley & Sons
KW  - NIH 3T3 Cells
KW  - PPAR gamma
KW  - Quinones
KW  - Receptor, Cannabinoid, CB1
KW  - Receptor, Cannabinoid, CB2
KW  - Skin
KW  - Structure-Activity Relationship
KW  - Animals
KW  - Bleomycin
KW  - Cannabidiol
KW  - Cell Differentiation
KW  - Cell Movement
KW  - Cells, Cultured
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Fibrosis
KW  - Humans
KW  - Inflammation
KW  - Mice
KW  - Mice, Inbred BALB C
KW  - Molecular Docking Simulation
KW  - Molecular Structure
TI  - VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways.
TY  - research article
VL  - 175
ER  -